Patient-derived neural and glioma stem cells were historically isolated on the basis of this marker [10,35,36]; however, many controversies surround the use of CD133 solely as a GSC marker, including studies showing that even CD133− cells can eventually give rise to CD133+ cells and form tumors in vivo [37,38]. This evidence concerns the gene PROM1 and glioma.